CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients
| Autor: | Azfar Shaikh, Delong Liu, Nasir Ahmed, Paul Baskind, Karen Seiter |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Risk Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Humans Cladribine Survival rate Aged Chemotherapy business.industry Remission Induction Cytarabine Myeloid leukemia Induction chemotherapy Induction Chemotherapy Hematology Middle Aged Granulocyte colony-stimulating factor Surgery Survival Rate Leukemia Myeloid Acute Regimen Treatment Outcome 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Leukemia Research. 46:74-78 |
| ISSN: | 0145-2126 |
| Popis: | The CLAG regimen is highly active in patients with relapsed and/or refractory acute myeloid leukemia (AML). We administered CLAG-based chemotherapy to 20 previously untreated AML patients who were poor candidates for standard induction therapy. Responding patients received further CLAG as post-remission therapy followed by additional therapy that was tailored to their AML subtype. Patients were considered poor candidates for standard therapy due to either cardiac disease, prior chemotherapy for another malignancy, prior myeloproliferative disease, or myelodysplastic syndrome that had progressed after hypomethylator therapy. Overall, thirteen patients had a complete response (CR) to the first cycle of therapy (65%), one patient had a CR without platelet recovery, and 3 patients had a partial response (PR). Two of the patients with PR converted to CR after further therapy. The median duration of response has not been reached; the mean duration of response is 36.8 months (95% CI 28.8-44.8 months). Median overall survival (including deaths from all causes) is 29.0 months (95% CI 18.0-46.0 months). Patients with de novo AML had a CR rate of 90.9% and a median overall survival of 38.5 months. CLAG-based therapy is a well-tolerated, efficacious induction strategy in previously-untreated patients with high risk AML. CLAG-based regimens should be studied in a broader group of newly diagnosed AML patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect